FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Diabetes Corporation of America dba DCA Pharmacy Sermorelin 6mg/6mL Lyophilized Powder Recall

Sermorelin 6mg/6mL Lyophilized Powder, Sterile Compound for Subcutaneous Injection, Dia…

Diabetes Corporation of America dba DCA Pharmacy · Franklin, TN

Risk level
Class II
Reported by FDA
Oct 14, 2015
Recall ID
D-0006-2016
Check your lot numberHow we source this data

Summary

Diabetes Corporation of America dba DCA Pharmacy recalled Sermorelin 6mg/6mL Lyophilized Powder starting Sep 23, 2015. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0006-2016 on Oct 14, 2015. Reason: Lack of Assurance of Sterility: A recent FDA inspection found that this product was not being compounded in an area appropriate for lyophilization which may lead to a lack of sterility assurance. Status: Terminated.

Why it was recalled

Lack of Assurance of Sterility: A recent FDA inspection found that this product was not being compounded in an area appropriate for lyophilization which may lead to a lack of sterility assurance.

Product description

Sermorelin 6mg/6mL Lyophilized Powder, Sterile Compound for Subcutaneous Injection, Diabetes Corporation of America dba DCA Pharmacy, Franklin, TN 37064-5527

Lot numbers, UPCs & expiration codes

Lot #: 101614, Exp 4/30/2015

Where it was sold

KY, OH, TN

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0006-2016
Classification
Class II
Status
Terminated
Recall initiated
Sep 23, 2015
FDA report date
Oct 14, 2015
Quantity
129 vials
Recall type
Voluntary: Firm initiated
Recalling firm
Diabetes Corporation of America dba DCA Pharmacy

Original FDA data

Every field from FDA enforcement report D-0006-2016, exactly as published.

Show all FDA fields
City
Franklin
State
TN
Status
Terminated
Country
United States
Event ID
72271
Address
233 Bedford Way
Code information
Lot #: 101614, Exp 4/30/2015
Postal code
37064-5527
Report date
Oct 14, 2015
Product type
Drugs
Recall number
D-0006-2016
Classification
Class II
Recalling firm
Diabetes Corporation of America dba DCA Pharmacy
Product quantity
129 vials
Termination date
Jan 12, 2016
Reason for recall
Lack of Assurance of Sterility: A recent FDA inspection found that this product was not being compounded in an area appropriate for lyophilization which may lead to a lack of sterility assurance.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Sermorelin 6mg/6mL Lyophilized Powder, Sterile Compound for Subcutaneous Injection, Diabetes Corporation of America dba DCA Pharmacy, Franklin, TN 37064-5527
Distribution pattern
KY, OH, TN
Recall initiation date
Sep 23, 2015
Initial firm notification
Telephone
Center classification date
Oct 5, 2015

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0006-2016, published Oct 14, 2015. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls